Clinical Trial Update: A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating 10 mg and 25 mg doses of etanercept for rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Etanercept (etanercept)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED